Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Infectious Disease · Aspergillosis

Can Aspergillus niger Be Mistaken for A. tubingensis?

At a Glance

Routine testing may not distinguish Aspergillus niger from A. tubingensis, so a report may say “A. niger complex.” A positive culture does not prove active infection; exact species testing matters most when the mold may be growing into tissue or antifungal treatment is failing.

Yes, Aspergillus niger can be difficult to distinguish from Aspergillus tubingensis on a standard lab report [1][2]. Because these fungi look nearly identical under a microscope, routine tests often group them together under the umbrella term “Aspergillus niger complex” [3].

Here are three key things to know if you see this on your report:

  1. A complex report is not a lab mistake: It is the standard way to report these visually identical fungi [3].
  2. Species identification is not always needed: Treatment depends heavily on whether the fungus is causing a superficial ear infection, living harmlessly in your airways, or actively invading tissue [4][1].
  3. A positive culture does not automatically mean you have an active infection: Finding Aspergillus in a sputum or ear swab requires your doctor to look at your symptoms and immune health before deciding if treatment is necessary [4][5]. Seek prompt medical attention for worsening breathing, chest pain, coughing blood, or fever, especially if you have a weakened immune system.

Why Misidentification Happens

The Aspergillus family is divided into groups, and Aspergillus niger belongs to a group of black-spored molds known as Aspergillus section Nigri [1]. When a laboratory grows a sample, members of this group share the same dark appearance and microscopic shape [3].

Because of this visual similarity, standard culture methods cannot reliably tell the difference between true Aspergillus niger (often called A. niger sensu stricto, meaning “in the strict sense”) and “cryptic” (hidden) relatives like A. tubingensis [6]. In some clinical studies where researchers used advanced testing on samples originally labeled as A. niger, they found that a substantial number were actually A. tubingensis [1][2]. However, this proportion varies widely depending on the study, the geographic region, and the type of sample.

Advanced Testing for Exact Identification

To tell these species apart, laboratories must rely on advanced techniques:

  • DNA Sequencing: The most reliable way to identify the exact species is by analyzing specific genes. Looking at genes called beta-tubulin (BenA) and calmodulin is highly effective at separating true A. niger from A. tubingensis [7][8].
  • MALDI-TOF MS: This technology identifies microbes by analyzing their proteins. While it can distinguish between species, its accuracy depends entirely on the laboratory’s reference database [9][10]. If the database is limited, the machine may incorrectly label a sample as A. niger instead of A. tubingensis [10].

Does the Exact Species Change Your Treatment?

Finding out you have A. tubingensis instead of true A. niger does not automatically mean your treatment will change. Your medical team will look at the whole picture.

The Importance of the Infection Site

  • Colonization or Contamination: If the fungus is just living in your airways without causing illness (colonization), or if it contaminated the sample, you generally will not need antifungal treatment [4].
  • Superficial Infection: For issues like fungal ear infections (otomycosis), exact species identification rarely changes the initial treatment plan [1].
  • Invasive Disease: If the fungus is actively growing into lung tissue (invasive disease), precise identification and specialized testing become much more critical [11][2].

Differences in Antifungal Susceptibility

The main medical reason exact identification can matter is antifungal susceptibility—how vulnerable the fungus is to medication [2]. In some laboratory studies, A. tubingensis has shown higher MICs (Minimum Inhibitory Concentrations) to common azole antifungal drugs, such as itraconazole, compared to true A. niger [12][13].

However, a higher MIC in the lab does not automatically mean the drug will fail in your body [14]. These results are population-dependent and must be interpreted by an infectious disease specialist [14]. If an infection is invasive and standard azole drugs are not working, your doctor will reassess your diagnosis, check your drug levels, and may consider alternative specialist-directed treatments, such as intravenous liposomal amphotericin B [15][16]. Never stop or adjust your antifungal medication without consulting your doctor.

If susceptibility testing is needed, labs use strict reference methods (like those from CLSI or EUCAST) because mold susceptibility testing has important technical limitations, and some standard commercial tests can be tricky to interpret accurately [2][17].

Common questions in this guide

Can routine testing tell Aspergillus niger from Aspergillus tubingensis?
Often it cannot. These molds can look nearly identical in routine culture and microscopy, so a laboratory may report them together as the Aspergillus niger complex. DNA sequencing or a protein-based test called MALDI-TOF can provide species-level identification when the laboratory has appropriate reference data.
What does an Aspergillus niger complex result mean?
It means the laboratory found a mold from a group of closely related black-spored Aspergillus species, but routine methods could not reliably identify the exact species. It is not necessarily a laboratory error and does not by itself prove that you have an active infection.
Does finding Aspergillus in a sputum or ear sample prove I need treatment?
No. The mold may be harmlessly present, may have contaminated the sample, or may be causing a superficial or invasive infection. Clinicians consider your symptoms, immune health, sample location, and signs of tissue invasion before recommending antifungal treatment.
Would treatment change if the mold is A. tubingensis instead of A. niger?
Not automatically. Species identification usually has more impact when infection is invasive, severe, or not responding to treatment; a superficial ear infection may initially be managed similarly. Your clinician or infectious disease specialist will combine the species result with the infection site and your overall condition.
Can Aspergillus tubingensis respond differently to common antifungal drugs?
Some laboratory studies have found higher MICs, or lower drug-sensitivity measurements, for certain azole medicines in A. tubingensis than in A. niger. A higher laboratory MIC does not guarantee that treatment will fail, so a specialist should interpret susceptibility results with the clinical picture and, when relevant, drug levels.
What symptoms need prompt medical attention?
Seek prompt medical attention for worsening breathing, chest pain, coughing blood, or fever, especially if your immune system is weakened. These symptoms can have many causes, but they should not be ignored when Aspergillus disease is being considered.

Get notified when new evidence is published on Aspergillus niger infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Clinical and microbial epidemiology of otomycosis in the city of Yasuj, southwest Iran, revealing Aspergillus tubingensis as the dominant causative agent.

    Sabz G, Gharaghani M, Mirhendi H, et al.

    Journal of medical microbiology 2019; (68(4)):585-590 doi:10.1099/jmm.0.000948.

    PMID: 30801244
  2. 2

    Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Aspergillus Section Nigri Isolates.

    Carrara B, Richards R, Imbert S, et al.

    Antimicrobial agents and chemotherapy 2020; (64(7)) doi:10.1128/AAC.02510-19.

    PMID: 32312779
  3. 3

    Aspergillus tubingensis: a major filamentous fungus found in the airways of patients with lung disease.

    Gautier M, Normand AC, L'Ollivier C, et al.

    Medical mycology 2016; (54(5)):459-70 doi:10.1093/mmy/myv118.

    PMID: 26773134
  4. 4

    Different repartition of the cryptic species of black aspergilli according to the anatomical sites in human infections, in a French University hospital.

    Gits-Muselli M, Hamane S, Verillaud B, et al.

    Medical mycology 2021; (59(10)):985-992 doi:10.1093/mmy/myab027.

    PMID: 34022772
  5. 5

    Diagnosis and Treatment of Invasive Aspergillosis Caused by Non-fumigatus Aspergillus spp.

    Stemler J, Többen C, Lass-Flörl C, et al.

    Journal of fungi (Basel, Switzerland) 2023; (9(4)) doi:10.3390/jof9040500.

    PMID: 37108955
  6. 6

    Identification of Aspergillus tubingensis in a primary skin infection.

    Frías-De-León MG, Rosas-de Paz E, Arenas R, et al.

    Journal de mycologie medicale 2018; (28(2)):274-278 doi:10.1016/j.mycmed.2018.02.013.

    PMID: 29551443
  7. 7

    Species identification, antifungal susceptibility, and clinical feature association of Aspergillus section Nigri isolates from the lower respiratory tract.

    Takeda K, Suzuki J, Watanabe A, et al.

    Medical mycology 2020; (58(3)):310-314 doi:10.1093/mmy/myz072.

    PMID: 31240316
  8. 8

    Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients.

    Kamali Sarwestani Z, Hashemi SJ, Rezaie S, et al.

    Journal de mycologie medicale 2018; (28(2)):279-284 doi:10.1016/j.mycmed.2018.02.003.

    PMID: 29540288
  9. 9

    Black aspergilli: A remaining challenge in fungal taxonomy?

    D'hooge E, Becker P, Stubbe D, et al.

    Medical mycology 2019; (57(6)):773-780 doi:10.1093/mmy/myy124.

    PMID: 30535052
  10. 10

    Molecular Analysis for Potential Hospital-Acquired Infection Caused by Aspergillus Tubingensis Through the Environment.

    Tanamachi C, Iwahashi J, Togo A, et al.

    The Kurume medical journal 2024; (69(3.4)):185-193 doi:10.2739/kurumemedj.MS6934013.

    PMID: 38233176
  11. 11

    Role of COPD in a case of fatal Aspergillus niger tracheobronchitis.

    Ashby T, Green K, Burcher KM, Louis M

    BMJ case reports 2023; (16(3)) doi:10.1136/bcr-2022-251807.

    PMID: 36948520
  12. 12

    The accuracy and clinical impact of the morphological identification of Aspergillus species in the age of cryptic species: A single-centre study.

    Takeda K, Suzuki J, Watanabe A, et al.

    Mycoses 2022; (65(2)):164-170 doi:10.1111/myc.13397.

    PMID: 34783396
  13. 13

    Epidemiological Characteristics of Clinical Aspergillus Section Nigri and Mutations in cyp51A Gene.

    Zhang Y, Zhang Y, Wang S, et al.

    Journal of fungi (Basel, Switzerland) 2026; (12(9)) doi:10.3390/jof12090683.

    PMID: 42783978
  14. 14

    Reduced Activity of Triazole Antifungal Agents Against Aspergillus tubingensis From a Global Collection of Genomically-Characterized Aspergillus Section Nigri Clinical Isolates (2020-2023).

    Kimbrough JH, Winkler ML, Karr MH, et al.

    Mycoses 2026; (69(7)):e70197 doi:10.1111/myc.70197.

    PMID: 42415524
  15. 15

    International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

    Verweij PE, Ananda-Rajah M, Andes D, et al.

    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2015; (21-22()):30-40.

    PMID: 26282594
  16. 16

    Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005).

    Wichmann D, Hoenigl M, Koehler P, et al.

    Infection 2025; (53(4)):1299-1310 doi:10.1007/s15010-025-02572-2.

    PMID: 40465080
  17. 17

    Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.

    Wang HC, Hsieh MI, Choi PC, Wu CJ

    Journal of clinical microbiology 2018; (56(10)) doi:10.1128/JCM.00780-18.

    PMID: 30093391

This page is for informational purposes only and does not constitute medical advice about an Aspergillus culture or treatment. Your clinician or infectious disease specialist should interpret the result alongside your symptoms, immune status, and sample site.